A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies

Trivedi, ND; Armstrong, S; Wang, HK; Hartley, M; Deeken, J; He, AR; Subramaniam, D; Melville, H; Albanese, C; Marshall, JL; Hwang, J; Pishvaian, MJ

Pishvaian, MJ (corresponding author), Johns Hopkins Univ, Dept Oncol, SKCC, Sch Med, 5255 Loughboro Rd NW, Washington, DC 20016 USA.

CANCER MEDICINE, 2021; 10 (6): 1944

Abstract

Background Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索